Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
09022-cover1-MAON401cxd.jpg

May 28, 2012 Cover

Volume 90, Issue 22

As pharmaceutical manufacturers increasingly use enzymatic reactions in their processes, a robust business model still eludes biocatalysis companies

Cover image:

Credit:

Full Article
Volume 90 | Issue 22

All Issues

Pharmaceuticals

Biocatalysis

As pharmaceutical manufacturers increasingly use enzymatic reactions in their processes, a robust business model still eludes biocatalysis companies

  • New Way To Modify DNA

    Zinc finger nickases may challenge zinc finger nucleases as genomic change agents

  • A Murky Case Of Technology Theft

    Claims and counterclaims obscure truth in case pitting U.S. resin maker against Chinese rival

  • Crowdsourcing Cures

    NIH initiative aims to partner academics with pharmaceutical companies to revive failed drug candidates

ADVERTISEMENT
image name
Physical Chemistry

How To Salvage Rejected X-ray Crystallography Data

Including diffraction data that’s usually thrown away could improve crystal structures

ADVERTISEMENT
ADVERTISEMENT